Clinical trials: Major Depressive Disorder in Pregnancy
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen
Depression, Postpartum, Postpartum Depression
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression
- Trial name
- NuMom (NCT06285916)
- Testing
- NORA520 Dose 1, NORA520 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 93 people
- Sponsor
- TWi Biotechnology, Inc.
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Severe Postpartum Depression
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum…
- Trial name
- NCT02614547
- Testing
- SAGE-547
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Severe Postpartum Depression
A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
The primary purpose of this study is to evaluate the safety and tolerability of BRII-296 administered by 2 intramuscular injections, administered with Depo Medrol as assessed by the incidence of adverse events, changes from…
- Trial name
- NCT06057012
- Testing
- BRII-296, Depo Medrol
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brii Biosciences Limited
Depression, Postpartum, Depression, Post-Partum
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression
- Trial name
- NCT06979544
- Testing
- LPCN 1154A
- Where
- 18 sites in United States
- Volunteers
- 90 people
- Sponsor
- Lipocine Inc.